598 related articles for article (PubMed ID: 36275727)
1. Target tumor microenvironment by innate T cells.
Li YR; Wilson M; Yang L
Front Immunol; 2022; 13():999549. PubMed ID: 36275727
[TBL] [Abstract][Full Text] [Related]
2. Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity.
Li YR; Brown J; Yu Y; Lee D; Zhou K; Dunn ZS; Hon R; Wilson M; Kramer A; Zhu Y; Fang Y; Yang L
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681730
[TBL] [Abstract][Full Text] [Related]
3. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
4. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
[TBL] [Abstract][Full Text] [Related]
5. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
6. An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy.
Li YR; Yu Y; Kramer A; Hon R; Wilson M; Brown J; Yang L
Cells; 2022 May; 11(9):. PubMed ID: 35563889
[TBL] [Abstract][Full Text] [Related]
7. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy.
Li YR; Zhou Y; Yu J; Zhu Y; Lee D; Zhu E; Li Z; Kim YJ; Zhou K; Fang Y; Lyu Z; Chen Y; Tian Y; Huang J; Cen X; Husman T; Cho JM; Hsiai T; Zhou JJ; Wang P; Puliafito BR; Larson SM; Yang L
Mol Ther; 2024 Jun; 32(6):1849-1874. PubMed ID: 38584391
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-Host Disease Modulation by Innate T Cells.
Fang Y; Zhu Y; Kramer A; Chen Y; Li YR; Yang L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835495
[TBL] [Abstract][Full Text] [Related]
9. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
10. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
11. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
[TBL] [Abstract][Full Text] [Related]
12. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
[TBL] [Abstract][Full Text] [Related]
13. Mucosal-associated invariant T cells for cancer immunotherapy.
Li YR; Zhou K; Wilson M; Kramer A; Zhu Y; Dawson N; Yang L
Mol Ther; 2023 Mar; 31(3):631-646. PubMed ID: 36463401
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
15. Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies.
Luo W; Napoleon JV; Zhang F; Lee YG; Wang B; Putt KS; Low PS
Front Immunol; 2022; 13():816761. PubMed ID: 35250995
[TBL] [Abstract][Full Text] [Related]
16. Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment.
Delfanti G; Dellabona P; Casorati G; Fedeli M
Front Med (Lausanne); 2022; 9():897750. PubMed ID: 35615083
[TBL] [Abstract][Full Text] [Related]
17. Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer.
Chen J; Zhu T; Jiang G; Zeng Q; Li Z; Huang X
Mol Cancer; 2023 Aug; 22(1):131. PubMed ID: 37563723
[TBL] [Abstract][Full Text] [Related]
18. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
Front Immunol; 2022; 13():863346. PubMed ID: 35874730
[TBL] [Abstract][Full Text] [Related]
19. Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.
Antoñana-Vildosola A; Zanetti SR; Palazon A
Int Rev Cell Mol Biol; 2022; 370():123-147. PubMed ID: 35798503
[TBL] [Abstract][Full Text] [Related]
20. Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.
Nikoo M; Rudiansyah M; Bokov DO; Jainakbaev NT; Suksatan W; Ansari MJ; Thangavelu L; Chupradit S; Zamani A; Adili A; Shomali N; Akbari M
J Cell Mol Med; 2022 Aug; 26(15):4137-4156. PubMed ID: 35762299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
